MedPath

Motiva Flora Tissue Expander PMCF

Not Applicable
Recruiting
Conditions
Breast Tissue Accessory
Breast Cancer
Interventions
Device: Breast Tissue Expander
Registration Number
NCT05447988
Lead Sponsor
Establishment Labs
Brief Summary

The Motiva Flora® Tissue Expander clinical study (hereafter Motiva Flora® TE study) is a 6-month, open-label, prospective, multicentre post-marketing follow-up study designed to confirm the Safety and Effectiveness/Performance of Motiva Flora® TE in breast reconstruction surgery.

The study will include 136 women, planned for staged breast reconstruction, in 6 countries (Spain, Belgium, France, Costa Rica, Chile and Panama). Breast tissue expansion and the final breast implant will be performed using devices from the Motiva Flora® TE catalogue.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
136
Inclusion Criteria

Not provided

Exclusion Criteria
  • The participant is pregnant or planning a pregnancy during the first year after surgery or is currently breastfeeding.
  • Participants with implanted devices that may be affected by magnetic fields (pacemakers, drug infusion devices).
  • Participants with abnormal haematological and biochemical values after chemotherapy.
  • Participants with tumour residues in or near the area where tissue expansion is to be performed.
  • Participants who do not have adequate tissue at the intended site for expansion, at the surgeon's discretion, due to previous radiotherapy, ulceration, vascular involvement, history of impaired wound healing or scar deformity.
  • Participants with current or previous infection in the area where the expansion will take place.
  • Presence of autoimmune diseases such as lupus or scleroderma, or immunocompromised participants due to immunosuppressive or steroid therapy.
  • Inadequate chest wall tissue due to damage caused by radiotherapy, tight skin grafts or radical resection of the pectoralis major muscle.
  • Participant who is included in another pharmacological or device research study.
  • Participants with a previous history of failure of attempted tissue expansion or breast implant placement at the site of intended expansion.
  • Participant with a history of silicone sensitivity.
  • Employees of Establishment Labs or any of its divisions or sites; Researchers or anyone who collaborates on the study or is directly related to a person working for Establishment Labs, sites or commissioned Researchers.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Two-stage reconstructionBreast Tissue Expander136 participants will undergo two-stage reconstruction
Primary Outcome Measures
NameTimeMethod
Incidence of the device and procedure-related adverse events6 months follow-up

Cumulative incidence of the device and procedure-related adverse events as assessed by occurrence, seriousness, severity, causal relationship with the device

Expected completion of breast tissue expansionUp to 6 months follow-up

Evaluate the time it took to reach the desired expansion following planning.

Perceived success of breast tissue expansion6 months follow-up

Success of the process as perceived by the investigator considering change in final breast volume and comparison with expected volume

Satisfaction assessed by the 5 point Likert scale6 months follow-up

- Surgeon's overall satisfaction (1=very significant improvement, 2=significant improvement, 3=improvement, 4=no change and 5=decline) at each follow-up visit.

Secondary Outcome Measures
NameTimeMethod
MRI and potential incidentsUp to 6 months follow-up

Incidents attributable to MR exposure.

Device interference on MRIUp to 6 months follow-up

Device interference on MRI measured through artifact size

Integrity of the fixing tabs defined as tabs being intact at explantationDuring the intervention/procedure/surgery for explantation

Observation of Integrity of the fixing tabs defined as tabs being intact at explanation with no detachments and cuts.

MRI and port locator performance measured through accurate locator functionUp to 6 months follow-up

Motiva Flora® Port locator performance after MRI measured through accurate location defined when the green light on the device comes on

In vivo testing of device interference with CT radiotherapy planning.Up to 6 months follow-up

Radiological Report after undergo CT:

- Interference with CT.

Trial Locations

Locations (5)

Centro Europeo de Cirugia

🇨🇷

San José, San Jose, Costa Rica

The Panama Clinic Complejo Hospitalario Pacific Center

🇵🇦

Panama, Panama

Centro de Patología de la Mama

🇪🇸

Madrid, Spain

Hospital Gregorio Marañón

🇪🇸

Madrid, Spain

Centro de Cirugía Plástica y Reconstructiva. Dra. Viviana Spröhnle Hospital Regional de Rancagua

🇨🇱

Rancagua, Chile

© Copyright 2025. All Rights Reserved by MedPath